Jim Kingsland's Financial Balderdash
Financial Reality For Those Who Can Handle the Truth
Monday, May 7, 2007
An analyst at Stanford lowered odds of approval for Dendreon's (DNDN) Provenge down to 40% from 80% following review of briefing documents. FDA to decide on the fate of Provenge by May 15th.
I remain long, but well hedged.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)